Literature DB >> 17148063

Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation.

Ulrica Forslöw1, Jonas Mattsson, Olle Ringden, Julius Klominek, Mats Remberger.   

Abstract

Pulmonary complications after allogeneic hematopoietic stem-cell transplantation (HSCT) remain 1 of the most important causes of morbidity and mortality. This study evaluates the change over time of incidence, aetiology and risk factors for death related to pneumonia within 3 months after HSCT. 997 patients who underwent HSCT were studied retrospectively. Most patients (83%) had a haematological malignancy. The majority (89%) had an HLA-A, -B, and -DR matched related or unrelated donor. Conditioning consisted of cyclophosphamide and total-body irradiation or busulfan and graft-versus-host disease prophylaxis of cyclosporin and methotrexate in most cases. Death related to pneumonia occurred in 56 (5.6%) patients. Cytomegalovirus (37%) was the main pathogen involved, especially during the first 2 decades studied. In the multivariate risk factor analysis, we found that death from pneumonia was significantly associated with receiving a T-cell depleted graft (p<0.001), bacteraemia (p=0.001), and y of transplantation (p<0.001). In patients receiving a transplant during the last decade, the incidence of death related to pneumonia was 2.8% compared to 8.9% during the first decade. We conclude that the rate of mortality related to pneumonia has decreased over time, possibly as a result of improved diagnostic, prophylactic and therapeutic methods and treatment.

Entities:  

Mesh:

Year:  2006        PMID: 17148063     DOI: 10.1080/00365540600786481

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  7 in total

1.  C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation.

Authors:  Mats Remberger; Jonas Mattsson
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

2.  A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.

Authors:  Johan Törlén; Olle Ringdén; Karin Garming-Legert; Per Ljungman; Jacek Winiarski; Kari Remes; Maija Itälä-Remes; Mats Remberger; Jonas Mattsson
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

Review 3.  Pulmonary Infections in Immunocompromised Hosts: Clinical.

Authors:  Cristina Vazquez Guillamet; Joe Le Hsu; Gundeep Dhillon; Rodrigo Vazquez Guillamet
Journal:  J Thorac Imaging       Date:  2018-09       Impact factor: 3.000

Review 4.  Bacterial Infections in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Elisa Balletto; Małgorzata Mikulska
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-07-01       Impact factor: 2.576

5.  Pulmonary Infection Within 100 Days After Transplantation Impaired Platelet Recovery in Patients with Hematologic Malignancies: A Propensity-Score-Matched Analysis.

Authors:  Roujia Wang; Aijie Huang; Qi Chen; Libing Wang; Lei Gao; Huiying Qiu; Xiong Ni; Weiping Zhang; Jianmin Yang; Jianmin Wang; Xiaoxia Hu
Journal:  Ann Transplant       Date:  2019-09-27       Impact factor: 1.530

6.  Pulmonary complications in hematopoietic SCT: a prospective study.

Authors:  C M Lucena; A Torres; M Rovira; M A Marcos; J P de la Bellacasa; M Sánchez; R Domingo; A Gabarrus; J Mensa; C Agustí
Journal:  Bone Marrow Transplant       Date:  2014-07-21       Impact factor: 5.483

7.  Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis.

Authors:  Karin Garming Legert; Olle Ringdén; Mats Remberger; Johan Törlén; Jonas Mattsson; Göran Dahllöf
Journal:  Oral Dis       Date:  2020-10-27       Impact factor: 3.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.